Amneal Pharmaceuticals Inc. logo

Amneal Pharmaceuticals Inc.

AMRX | NASDAQ
Chart Builder DCF Calculator
$20.16
+$1.45 (+7.75%)
At close: Sep 21, 2026, 4:00 PM ET
$20.88
+$0.72 (+3.57%)
Pre-market: Sep 22, 2026, 8:00 AM ET

Company Profile

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Key Executives

Name Position
Chintu Patel Co-Founder, Co-CEO & Director
Chirag K. Patel Co-Founder, Co-CEO, President & Director
Anastasios G. Konidaris Executive Vice President & Chief Financial Officer
Jason Daly Executive Vice President, Chief Legal Officer & Corporate Secretary
Andrew S. Boyer Executive Vice President and Chief Commercial Officer of Generics & Biosciences
Anthony DiMeo Head/VP of Investor Relations
Brandon Skop Senior Director of Corporate Communications
Gregory Sgammato Senior Vice President of Corporate Development
Nikita Shah Executive Vice President & Chief Human Resources Officer
Pranav Mehta Senior Vice President of Strategic Sourcing & Supply Management
Sanjay Kumar Jain Chief Quality Officer

Latest SEC Filings

Date Type Title
Sep 03, 2026 S-3ASR Automatic shelf registration statement of securiti...
Sep 02, 2026 4 Filing
Aug 25, 2026 4 Filing
Aug 14, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 12, 2026 144 Filing
Aug 12, 2026 144 Filing
Aug 12, 2026 4 Filing
View All SEC Filings
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. logo
Country United States
IPO Date May 6, 2018
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 8,700
CEO Chirag K. Patel

Contact Details

400 Crossing Boulevard Bridgewater, New Jersey 08807 United States

Stock Details

Ticker Symbol AMRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001723128
CUSIP Number 03168L105
ISIN Number US03168L1052
SIC Code 2834

© 2026 bestshares.com. All rights reserved.